Ratings Neogen Corporation

Equities

NEOG

US6404911066

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
12.14 ^USD	+1.51%		+4.57%	-39.63%

18/04	Neogen Corporation Forms Genomics Relationship with Performance Food Group	CI
15/04	Piper Sandler Adjusts Price Target on Neogen to $17 From $19, Maintains Neutral Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company has insufficient levels of profitability.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
NEOGEN CORPORATION	-39.63%	2.63B	C
ABBOTT LABORATORIES	-2.31%	187B	C+
MEDTRONIC PLC	-3.20%	106B	C
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B	A
DEXCOM, INC.	+0.20%	49.45B	B-
CENCORA, INC.	+17.29%	48B	B-
HOYA CORPORATION	+4.06%	40.84B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B	B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B	A-
TERUMO CORPORATION	+12.96%	24.62B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes